Youxin Zhou

899 Pinghai Road
Suzhou, 215000, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 66 publications

Establishment of a Novel IDH1 wild type Glioblastoma Cell Line, SHG142, and Its Organoids.

Establishment of a Novel IDH1 wild type Glioblastoma Cell Line, SHG142, and Its Organoids.

Journal: Frontiers in bioscience (Landmark edition)

Published: December 12, 2025

PAK4 functions as an immune suppressor by reprogramming the phosphatidylcholine metabolism of CD8 + T cells within the glioblastoma tumor microenvironment.

PAK4 functions as an immune suppressor by reprogramming the phosphatidylcholine metabolism of CD8 + T cells within the glioblastoma tumor microenvironment.

Journal: Oncogene

Published: October 01, 2025

TRAP1 promotes self-renewal and tumorigenicity of glioblastoma stem cells by inhibiting Notch1 ubiquitination.

TRAP1 promotes self-renewal and tumorigenicity of glioblastoma stem cells by inhibiting Notch1 ubiquitination.

Journal: Biochemical and biophysical research communications

Published: June 08, 2025

Overexpression of PLK1 promotes autophagy-mediated resistance to TMZ in glioblastoma cells by activating NPM1.

Overexpression of PLK1 promotes autophagy-mediated resistance to TMZ in glioblastoma cells by activating NPM1.

Journal: Biochemical and biophysical research communications

Published: March 29, 2025

Cisplatin reduces immunosuppression caused by tumor-associated macrophages through downregulating CD47-SIRPα signaling in glioblastoma.

Cisplatin reduces immunosuppression caused by tumor-associated macrophages through downregulating CD47-SIRPα signaling in glioblastoma.

Journal: Biochimica et biophysica acta. Molecular basis of disease

Published: October 11, 2024

BRD4 promotes immune escape of glioma cells by upregulating PD-L1 expression.

BRD4 promotes immune escape of glioma cells by upregulating PD-L1 expression.

Journal: Journal of neuro-oncology

Published: October 05, 2024

Combined anti-PD-L1 and anti-VEGFR2 therapy promotes the antitumor immune response in GBM by reprogramming tumor microenvironment.

Combined anti-PD-L1 and anti-VEGFR2 therapy promotes the antitumor immune response in GBM by reprogramming tumor microenvironment.

Journal: Cell death discovery

Published: July 25, 2024

The dual role of POSTN in maintaining glioblastoma stem cells and the immunosuppressive phenotype of microglia in glioblastoma.

The dual role of POSTN in maintaining glioblastoma stem cells and the immunosuppressive phenotype of microglia in glioblastoma.

Journal: Journal of experimental & clinical cancer research : CR

Published: June 14, 2024

Suberanilohydroxamic acid (SAHA), a HDAC inhibitor, suppresses the effect of Treg cells by targeting the c-Myc/CCL1 pathway in glioma stem cells and improves PD-L1 blockade therapy.

Suberanilohydroxamic acid (SAHA), a HDAC inhibitor, suppresses the effect of Treg cells by targeting the c-Myc/CCL1 pathway in glioma stem cells and improves PD-L1 blockade therapy.

Journal: Journal of neuro-oncology

Published: March 18, 2024

TAK-242 inhibits glioblastoma invasion, migration, and proneural-mesenchymal transition by inhibiting TLR4 signaling.

TAK-242 inhibits glioblastoma invasion, migration, and proneural-mesenchymal transition by inhibiting TLR4 signaling.

Journal: Experimental cell research

Published: January 11, 2024

A blood blister-like aneurysm occurring on an intracranial dissecting aneurysm: A case report.

A blood blister-like aneurysm occurring on an intracranial dissecting aneurysm: A case report.

Journal: Asian journal of surgery

Published: December 06, 2023

A case of primary central-nervous system lymphoma with no obvious effect of hormone therapy.

A case of primary central-nervous system lymphoma with no obvious effect of hormone therapy.

Journal: Asian journal of surgery

Published: November 28, 2023

Showing 1-12 of 66

Last Updated: 09/26/2026